On the occasion of the 8th annual meeting of the European Society for Molecular Imaging in Torino (26 to 28 May, 2013) Françoise Cailler, CEO of SurgiMab, will present the company’s R&D programs during the “Intra-Operative Imaging” session, Monday May 27th at 3:00 pm in a short oral presentation. A poster will also be presented Tuesday May 28th from 9:00 to 10:30 (Framery et al, Intraoperative near-infrared immuno photodetection of advanced ovarian tumors with the use of a novel specific conjugate targeting AMHRII. Poster n°177.)
On the occasion of the Grenoble EuroMedtech meeting that took place between May 31st and June 1st 2012, Françoise Cailler, SurgiMab’s president, answered BioPharmInsight’s questions (the Financial Times group). She describes the next steps for SurgiMab in terms of development.
Read the article: SurgiMAB to sign a deal with French CMO…
OSEO, a public institution promoting the innovation and growth of SMEs, awarded SurgiMab the status of Innovative Enterprise and its FCPI certification (Mutual Funds for Innovation) in April.
Convinced by the development program that was launched by the young start-up and by the dynamic team that was installed, and following the obtention of a 450 000 € aid from Oseo / Languedoc-Roussillon Region, SurgiMab’s investors decided to consolidate their initial engagement, allowing the company to seure its R&D program up to the start of the clinical trials for its first molecule.
The realization of this investment demonstrated the capacity of the founding team to federate all necessary actors for a quick development of SurgiMab’s fluorescent conjugates. “These seeding funds, added to the institutional help and the initial investment from our partners allows to foresee the first clinical assays in 2013, to propose our technology to patients as quickly and directly as possible” says Françoise Cailler, President of SurgiMab.
In order to finalize the clinical studies that are compulsory for the development of its products, the company will prepare a new funds raising at the beginning of 2013.
Read the article published in “Biotech Finances” on February 20th, 2012.
Read the Press Release (French)
Following its creation in July 2011, the company now anounces a first round of financing of 500 000 Euros. If the conditions are filled, this first round will be completed at the begining of 2012 following conditions that were defined with the present financial partners : Cathey World Investment Ltd., and ABALIS Finances AG.
This financing will allow SurgiMab to finalize the pre-clinical development of its first conjugate targeting digestive tumors and to set up the first clinical assays that should take place within Montpellier’s Val d’Aurelle Regional Anti-Cancer Center. SurgiMAb was assisted for this operation by the Law Firm Brunswick and by Biotech Developement Conseil.
Link to the Press Release (in French)
SurgiMAb wins in the Heath Category.
SurgiMAb was designed by the jury of “Capital Transfert 2009” as the winner of the Trophy “Entrepreneur Santé” of the year.
After being chosen among the 18 pre-selected projects, Françoise Cailler received her Trophy from Mr. Philippe Adnot, Senator, during the closing ceremony of this event at Pitié Salpêtrière university of Medecine in Paris.